Silver Spring, MD – September 25, 2025 — Pinco Biotherapeutics announced that it presented its novel pain therapeutic at the 2025 BioHealth Capital Region Forum, part of BioHealth Capital Region Week.

The forum brings together emerging biotech companies, regional investors, federal stakeholders, and strategic partners across Maryland, Washington, DC, and Virginia. Pinco presented during the event’s additional company pitch sessions, highlighting its DNA plasmid–based approach targeting Nav1.7 for neuropathic pain.

The presentation focused on:

• The significant unmet need in chronic neuropathic pain

• Genetic validation of Nav1.7 as a therapeutic target

• Early in-vitro data demonstrating depletion of Nav1.7 expression

• A defined preclinical development pathway toward Phase I

“BioHealth Capital Region Week is an important platform for regional biotech visibility,” said Alpizar. “Presenting our data and ambition in front of investors and ecosystem partners allowed us to strengthen relationships within the Mid-Atlantic life sciences community as we continue building toward in-vivo proof-of-concept.”

About Pinco Biotherapeutics

Pinco Biotherapeutics is a preclinical therapeutics company developing non-viral DNA plasmid–based drugs for chronic neuropathic pain. By directly targeting validated molecular drivers of pain, Pinco’s plasmid is designed to deliver durable, non-addictive relief while avoiding the systemic side effects of small molecules and the immunogenicity risks of viral gene therapies.